| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumonia | 9 | 2022 | 196 | 3.380 |
Why?
|
| Community-Acquired Infections | 9 | 2022 | 65 | 2.470 |
Why?
|
| Patient Discharge | 6 | 2023 | 361 | 1.880 |
Why?
|
| Hospitalization | 8 | 2023 | 943 | 1.650 |
Why?
|
| Hospital Medicine | 2 | 2023 | 27 | 1.480 |
Why?
|
| Physicians | 7 | 2021 | 706 | 1.340 |
Why?
|
| Sepsis | 3 | 2024 | 389 | 1.210 |
Why?
|
| Length of Stay | 8 | 2023 | 833 | 1.190 |
Why?
|
| Severity of Illness Index | 5 | 2024 | 1981 | 1.120 |
Why?
|
| Patient Readmission | 8 | 2025 | 413 | 1.090 |
Why?
|
| Neuroblastoma | 6 | 2017 | 400 | 1.050 |
Why?
|
| Patient Satisfaction | 4 | 2020 | 514 | 1.020 |
Why?
|
| Hospital Mortality | 5 | 2024 | 483 | 1.010 |
Why?
|
| Clinical Coding | 3 | 2024 | 23 | 1.010 |
Why?
|
| Decision Making | 7 | 2021 | 694 | 1.000 |
Why?
|
| Internship and Residency | 4 | 2022 | 1134 | 0.840 |
Why?
|
| Copyright | 2 | 2013 | 2 | 0.810 |
Why?
|
| Publishing | 1 | 2024 | 94 | 0.790 |
Why?
|
| Medical Overuse | 2 | 2021 | 40 | 0.790 |
Why?
|
| Skilled Nursing Facilities | 1 | 2023 | 49 | 0.780 |
Why?
|
| Physician-Patient Relations | 5 | 2021 | 635 | 0.760 |
Why?
|
| Cross Infection | 2 | 2021 | 159 | 0.760 |
Why?
|
| Humans | 60 | 2025 | 95802 | 0.750 |
Why?
|
| Comorbidity | 4 | 2018 | 1011 | 0.690 |
Why?
|
| Medicare | 4 | 2022 | 458 | 0.690 |
Why?
|
| Universal Precautions | 1 | 2021 | 4 | 0.680 |
Why?
|
| Respiratory Insufficiency | 2 | 2022 | 205 | 0.680 |
Why?
|
| Mental Fatigue | 1 | 2021 | 9 | 0.680 |
Why?
|
| Personal Autonomy | 1 | 2021 | 120 | 0.650 |
Why?
|
| United States | 18 | 2022 | 7764 | 0.640 |
Why?
|
| Patient Preference | 2 | 2020 | 126 | 0.620 |
Why?
|
| Hospitalists | 1 | 2021 | 143 | 0.610 |
Why?
|
| Occupational Exposure | 1 | 2020 | 89 | 0.590 |
Why?
|
| Education, Medical, Graduate | 2 | 2013 | 436 | 0.590 |
Why?
|
| Marital Status | 1 | 2019 | 45 | 0.590 |
Why?
|
| Patient Participation | 2 | 2020 | 241 | 0.580 |
Why?
|
| Health Personnel | 1 | 2021 | 241 | 0.580 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 468 | 0.570 |
Why?
|
| Mesenteric Vascular Occlusion | 1 | 2018 | 20 | 0.570 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2018 | 36 | 0.570 |
Why?
|
| Splenic Diseases | 1 | 2018 | 14 | 0.570 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 346 | 0.560 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 334 | 0.560 |
Why?
|
| Pancreatitis | 1 | 2018 | 94 | 0.540 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2017 | 246 | 0.530 |
Why?
|
| Data Collection | 1 | 2018 | 381 | 0.520 |
Why?
|
| Endoscopy, Digestive System | 1 | 2017 | 72 | 0.510 |
Why?
|
| Colonic Diseases | 1 | 2017 | 61 | 0.500 |
Why?
|
| Gastroenterologists | 1 | 2017 | 31 | 0.500 |
Why?
|
| Pharmacogenetics | 3 | 2025 | 456 | 0.490 |
Why?
|
| Ambulatory Care | 2 | 2016 | 198 | 0.490 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 257 | 0.480 |
Why?
|
| Mass Screening | 1 | 2021 | 710 | 0.480 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 296 | 0.470 |
Why?
|
| Inpatients | 6 | 2025 | 347 | 0.470 |
Why?
|
| Communication | 2 | 2016 | 478 | 0.470 |
Why?
|
| Periodicals as Topic | 2 | 2024 | 171 | 0.460 |
Why?
|
| Patient-Centered Care | 4 | 2021 | 228 | 0.450 |
Why?
|
| Pandemics | 2 | 2020 | 880 | 0.440 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 491 | 0.440 |
Why?
|
| Colonoscopy | 1 | 2017 | 304 | 0.440 |
Why?
|
| Logistic Models | 6 | 2019 | 1267 | 0.440 |
Why?
|
| Terminal Care | 1 | 2016 | 146 | 0.430 |
Why?
|
| Hospital-Physician Joint Ventures | 1 | 2014 | 4 | 0.430 |
Why?
|
| Constipation | 1 | 2015 | 69 | 0.430 |
Why?
|
| Comprehensive Health Care | 1 | 2014 | 14 | 0.420 |
Why?
|
| Palliative Care | 1 | 2016 | 271 | 0.420 |
Why?
|
| Socioeconomic Factors | 5 | 2024 | 640 | 0.420 |
Why?
|
| Office Visits | 1 | 2014 | 52 | 0.420 |
Why?
|
| Male | 27 | 2025 | 45686 | 0.410 |
Why?
|
| Waiting Lists | 2 | 2015 | 212 | 0.410 |
Why?
|
| Health Status Indicators | 1 | 2014 | 104 | 0.410 |
Why?
|
| Aged | 20 | 2025 | 20848 | 0.410 |
Why?
|
| Intensive Care Units | 2 | 2024 | 460 | 0.400 |
Why?
|
| Hospital Costs | 1 | 2014 | 117 | 0.400 |
Why?
|
| Critical Care | 1 | 2016 | 447 | 0.380 |
Why?
|
| Middle Aged | 21 | 2025 | 28208 | 0.380 |
Why?
|
| Aged, 80 and over | 10 | 2025 | 7215 | 0.370 |
Why?
|
| Holidays | 1 | 2011 | 4 | 0.360 |
Why?
|
| Wit and Humor as Topic | 1 | 2011 | 13 | 0.360 |
Why?
|
| Hospitals, General | 1 | 2011 | 12 | 0.360 |
Why?
|
| Famous Persons | 1 | 2011 | 8 | 0.360 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 647 | 0.350 |
Why?
|
| Teaching Rounds | 1 | 2011 | 26 | 0.350 |
Why?
|
| Female | 25 | 2025 | 49872 | 0.350 |
Why?
|
| Personal Protective Equipment | 2 | 2021 | 37 | 0.340 |
Why?
|
| Adult | 20 | 2025 | 28578 | 0.340 |
Why?
|
| Art | 1 | 2010 | 5 | 0.330 |
Why?
|
| Search Engine | 1 | 2010 | 12 | 0.330 |
Why?
|
| Risk Factors | 9 | 2018 | 5961 | 0.320 |
Why?
|
| Infection Control | 2 | 2021 | 132 | 0.300 |
Why?
|
| Sex Factors | 4 | 2018 | 1127 | 0.300 |
Why?
|
| Terminology as Topic | 1 | 2010 | 227 | 0.290 |
Why?
|
| Age Factors | 4 | 2018 | 1957 | 0.290 |
Why?
|
| Internet | 1 | 2010 | 340 | 0.270 |
Why?
|
| Academic Medical Centers | 3 | 2020 | 422 | 0.270 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2017 | 18 | 0.260 |
Why?
|
| Pharmacogenomic Testing | 2 | 2025 | 107 | 0.250 |
Why?
|
| Serum Albumin, Bovine | 1 | 2016 | 47 | 0.250 |
Why?
|
| Osteonectin | 1 | 2016 | 22 | 0.250 |
Why?
|
| Palmitic Acid | 1 | 2016 | 29 | 0.250 |
Why?
|
| Acute Disease | 2 | 2021 | 859 | 0.250 |
Why?
|
| Chicago | 4 | 2020 | 1505 | 0.250 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2017 | 125 | 0.240 |
Why?
|
| Antithrombin III Deficiency | 1 | 2005 | 3 | 0.240 |
Why?
|
| Trisomy | 1 | 2005 | 53 | 0.230 |
Why?
|
| Behcet Syndrome | 1 | 2005 | 15 | 0.230 |
Why?
|
| Emergency Service, Hospital | 2 | 2023 | 593 | 0.230 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2005 | 83 | 0.230 |
Why?
|
| Mosaicism | 1 | 2005 | 74 | 0.230 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 220 | 0.230 |
Why?
|
| Odds Ratio | 3 | 2019 | 713 | 0.230 |
Why?
|
| Genes, myc | 1 | 2015 | 41 | 0.230 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 353 | 0.220 |
Why?
|
| Oncogene Proteins | 1 | 2015 | 65 | 0.220 |
Why?
|
| Intestinal Diseases | 1 | 2005 | 85 | 0.220 |
Why?
|
| Obesity | 1 | 2011 | 1030 | 0.220 |
Why?
|
| Bone Neoplasms | 1 | 2017 | 316 | 0.220 |
Why?
|
| Writing | 1 | 2024 | 31 | 0.210 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2025 | 123 | 0.210 |
Why?
|
| Diagnostic Errors | 1 | 2024 | 158 | 0.200 |
Why?
|
| Drug Prescriptions | 1 | 2025 | 151 | 0.200 |
Why?
|
| Residence Characteristics | 1 | 2024 | 213 | 0.190 |
Why?
|
| Patient Care Team | 1 | 2025 | 307 | 0.180 |
Why?
|
| Risk Assessment | 3 | 2018 | 2480 | 0.180 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2005 | 377 | 0.180 |
Why?
|
| Informed Consent | 2 | 2021 | 281 | 0.180 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 57 | 0.170 |
Why?
|
| Occupations | 1 | 2021 | 24 | 0.170 |
Why?
|
| Goals | 1 | 2021 | 68 | 0.170 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 33 | 0.170 |
Why?
|
| Euthanasia, Passive | 1 | 2000 | 16 | 0.170 |
Why?
|
| Treatment Refusal | 1 | 2021 | 68 | 0.170 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 750 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 684 | 0.160 |
Why?
|
| Lymph Nodes | 1 | 2014 | 554 | 0.160 |
Why?
|
| Suicide, Assisted | 1 | 2000 | 36 | 0.160 |
Why?
|
| Betacoronavirus | 2 | 2020 | 284 | 0.160 |
Why?
|
| Risk Management | 1 | 2020 | 43 | 0.160 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 79 | 0.160 |
Why?
|
| Patient Advocacy | 1 | 2000 | 64 | 0.160 |
Why?
|
| Internal Medicine | 2 | 2014 | 371 | 0.160 |
Why?
|
| Truth Disclosure | 1 | 2000 | 92 | 0.160 |
Why?
|
| Attitude | 1 | 2000 | 137 | 0.150 |
Why?
|
| DNA Methylation | 1 | 2014 | 703 | 0.150 |
Why?
|
| Attitude to Health | 1 | 2021 | 226 | 0.150 |
Why?
|
| Workload | 1 | 2020 | 133 | 0.150 |
Why?
|
| Prospective Studies | 4 | 2025 | 4664 | 0.150 |
Why?
|
| Mobility Limitation | 1 | 2019 | 20 | 0.150 |
Why?
|
| Medicaid | 1 | 2022 | 260 | 0.150 |
Why?
|
| Splenic Vein | 1 | 2018 | 5 | 0.140 |
Why?
|
| Gastric Fundus | 1 | 2018 | 7 | 0.140 |
Why?
|
| Retrospective Studies | 5 | 2023 | 10273 | 0.140 |
Why?
|
| Risk Adjustment | 1 | 2018 | 40 | 0.140 |
Why?
|
| Mesenteric Veins | 1 | 2018 | 36 | 0.140 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1267 | 0.140 |
Why?
|
| Ethics, Medical | 1 | 2000 | 312 | 0.140 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 848 | 0.140 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1008 | 0.130 |
Why?
|
| Prognosis | 3 | 2016 | 3990 | 0.130 |
Why?
|
| Steroids | 1 | 2018 | 173 | 0.130 |
Why?
|
| Health Services | 1 | 2017 | 58 | 0.130 |
Why?
|
| Negotiating | 1 | 2016 | 20 | 0.120 |
Why?
|
| Transitional Care | 1 | 2016 | 20 | 0.120 |
Why?
|
| Medication Reconciliation | 1 | 2016 | 7 | 0.120 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 1765 | 0.120 |
Why?
|
| Home Care Services | 1 | 2017 | 77 | 0.120 |
Why?
|
| Managed Care Programs | 1 | 1996 | 43 | 0.120 |
Why?
|
| Cohort Studies | 4 | 2016 | 3106 | 0.120 |
Why?
|
| Employment | 1 | 1996 | 57 | 0.120 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 682 | 0.110 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 67 | 0.110 |
Why?
|
| Career Choice | 1 | 1997 | 163 | 0.110 |
Why?
|
| Medical Records | 1 | 2015 | 125 | 0.110 |
Why?
|
| Research Design | 1 | 2018 | 630 | 0.110 |
Why?
|
| Cell Hypoxia | 2 | 2016 | 187 | 0.110 |
Why?
|
| Pneumonia, Bacterial | 1 | 2014 | 30 | 0.110 |
Why?
|
| Cell Line, Tumor | 3 | 2016 | 2777 | 0.110 |
Why?
|
| Disease Management | 1 | 2017 | 360 | 0.110 |
Why?
|
| Patient Handoff | 1 | 2016 | 100 | 0.110 |
Why?
|
| Empathy | 1 | 2016 | 155 | 0.110 |
Why?
|
| Cost Control | 1 | 2014 | 45 | 0.110 |
Why?
|
| Surveys and Questionnaires | 3 | 2016 | 2859 | 0.110 |
Why?
|
| Health Services Research | 1 | 2014 | 148 | 0.100 |
Why?
|
| Trust | 1 | 2013 | 101 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2015 | 1540 | 0.090 |
Why?
|
| Massachusetts | 1 | 2011 | 35 | 0.090 |
Why?
|
| Quality of Health Care | 1 | 2015 | 403 | 0.090 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 1194 | 0.090 |
Why?
|
| Students, Medical | 1 | 1997 | 455 | 0.090 |
Why?
|
| Pneumococcal Vaccines | 1 | 2011 | 33 | 0.080 |
Why?
|
| Insurance Claim Review | 1 | 2011 | 47 | 0.080 |
Why?
|
| Streptococcus pneumoniae | 1 | 2011 | 56 | 0.080 |
Why?
|
| Sex Distribution | 1 | 2011 | 175 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2017 | 9167 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2016 | 854 | 0.080 |
Why?
|
| Age Distribution | 1 | 2011 | 209 | 0.080 |
Why?
|
| Outpatients | 1 | 2011 | 105 | 0.080 |
Why?
|
| Anti-Infective Agents | 1 | 2011 | 96 | 0.080 |
Why?
|
| Mortality | 1 | 2011 | 154 | 0.080 |
Why?
|
| Young Adult | 3 | 2025 | 7026 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2014 | 502 | 0.080 |
Why?
|
| Diabetes Complications | 1 | 2011 | 175 | 0.080 |
Why?
|
| Precision Medicine | 2 | 2025 | 454 | 0.080 |
Why?
|
| Time Factors | 2 | 2018 | 5561 | 0.080 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 900 | 0.070 |
Why?
|
| Adolescent | 3 | 2016 | 9873 | 0.070 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2017 | 20 | 0.070 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 60 | 0.060 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 70 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2017 | 147 | 0.060 |
Why?
|
| Incidence | 1 | 2011 | 1714 | 0.060 |
Why?
|
| Specialization | 2 | 1997 | 68 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 204 | 0.060 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2015 | 40 | 0.060 |
Why?
|
| Consensus | 1 | 2017 | 370 | 0.060 |
Why?
|
| Neoplasms | 1 | 2000 | 3242 | 0.060 |
Why?
|
| Cyclohexylamines | 1 | 2014 | 8 | 0.050 |
Why?
|
| Cell Survival | 1 | 2016 | 1029 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2016 | 382 | 0.050 |
Why?
|
| Response Elements | 1 | 2014 | 65 | 0.050 |
Why?
|
| Loss of Heterozygosity | 1 | 2014 | 85 | 0.050 |
Why?
|
| Mixed Function Oxygenases | 1 | 2014 | 69 | 0.050 |
Why?
|
| Quality Control | 1 | 2014 | 125 | 0.050 |
Why?
|
| Cytosine | 1 | 2014 | 135 | 0.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2014 | 135 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2014 | 297 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 292 | 0.050 |
Why?
|
| 5-Methylcytosine | 1 | 2014 | 122 | 0.050 |
Why?
|
| Child | 2 | 2015 | 7618 | 0.050 |
Why?
|
| Cell Movement | 1 | 2016 | 816 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 170 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 299 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 1827 | 0.050 |
Why?
|
| Pharmacists | 1 | 2022 | 36 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 1878 | 0.050 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 506 | 0.050 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 562 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2014 | 740 | 0.040 |
Why?
|
| Cross-Cultural Comparison | 1 | 2000 | 35 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1753 | 0.040 |
Why?
|
| Heart Failure | 1 | 2011 | 1422 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2014 | 644 | 0.040 |
Why?
|
| Japan | 1 | 2000 | 313 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 1079 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 555 | 0.040 |
Why?
|
| Models, Biological | 1 | 2016 | 1809 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2000 | 239 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 1346 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 2042 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2020 | 245 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2015 | 1662 | 0.040 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2018 | 66 | 0.030 |
Why?
|
| Phenotype | 1 | 2014 | 2575 | 0.030 |
Why?
|
| Infant | 1 | 2014 | 3360 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2014 | 1422 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 231 | 0.030 |
Why?
|
| General Practice | 1 | 2016 | 9 | 0.030 |
Why?
|
| Medicine | 1 | 1997 | 97 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 2494 | 0.030 |
Why?
|
| California | 1 | 1996 | 161 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 2473 | 0.030 |
Why?
|
| Forecasting | 1 | 1996 | 317 | 0.030 |
Why?
|
| Self Care | 1 | 2016 | 170 | 0.030 |
Why?
|
| Perception | 1 | 2015 | 185 | 0.030 |
Why?
|
| Social Support | 1 | 2016 | 239 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1096 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2013 | 199 | 0.020 |
Why?
|
| Patient Admission | 1 | 2013 | 122 | 0.020 |
Why?
|
| Education, Medical | 1 | 1996 | 252 | 0.020 |
Why?
|
| Health Surveys | 1 | 2013 | 245 | 0.020 |
Why?
|
| Mice | 1 | 2016 | 12537 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 2039 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 2015 | 0.020 |
Why?
|
| Animals | 1 | 2016 | 28889 | 0.020 |
Why?
|
| Hyperthermia, Induced | 2 | 1956 | 75 | 0.010 |
Why?
|
| Rhinitis, Allergic, Seasonal | 2 | 1956 | 179 | 0.010 |
Why?
|
| Immunization, Passive | 1 | 1953 | 75 | 0.010 |
Why?
|
| Agglutinins | 1 | 1950 | 4 | 0.010 |
Why?
|
| Typhoid Fever | 1 | 1950 | 4 | 0.010 |
Why?
|
| Typhoid-Paratyphoid Vaccines | 1 | 1950 | 5 | 0.010 |
Why?
|
| Agglutination | 1 | 1950 | 16 | 0.010 |
Why?
|
| Serologic Tests | 1 | 1950 | 43 | 0.000 |
Why?
|